Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Copaxone

- PMLiVE

Stories of sickness: applying illness narratives to health advertising

By Dr Stephanie Goley Introduction As advertisers, we know that health and pharmaceutical campaigns hold enormous influence over how the public perceives illness, wellness, and treatment. But too often, our...

11 London

- PMLiVE

11 London and B Corp

Three years ago, 11 London became the first UK health agency to gain B-Corp accreditation. CEO and Co-Founder, Matt Hunt reports back on life in the B-List...

11 London

- PMLiVE

Sanofi and Alloy Therapeutics enter central nervous system deal worth over $427m

The agreement allows Sanofi to use Alloy’s antisense platform for a central nervous system target

Health advertising

The key to HCP engagement: 5 Tips for pharma marketers

Did you know that in 2023 in the US, the pharma industry spent approximately USD 15.84 billion on digital advertising? The US healthcare industry is expected to grow to 29.2...

Wiley

- PMLiVE

Health awareness days in May

Are you marketing to clinical audiences around upcoming health awareness days?

Springer Nature

- PMLiVE

King’s College London and 11 London collaborate on health psychology

We’re delighted to announce that we are working in partnership with the Health Psychology department at King's College London. Professor Rona Moss-Morris is working with the agency on a shared...

11 London

- PMLiVE

FDA approves Alvotech and Teva’s Simlandi as interchangeable Humira biosimilar

Simlandi is approved to treat multiple indications, including rheumatoid arthritis and Crohn’s disease

Healthcare professionals seek independent medical education (IME)

The evolving healthcare advertising landscape

Industry experts share their insights on the emerging trends in healthcare advertising

Wiley

Matt Hunt

How we’re making AI a part of life at 11 London

This article talks about how AI is being used more in advertising, showing how it can change the way things are done from planning out strategies to coming up with...

11 London

- PMLiVE

New UK study finds most MS patients not offered fatigue treatments

Of 4,367 patients surveyed, 30.8% reported having been offered at least one treatment for fatigue

- PMLiVE

Teva and Allergan finalise terms of US opioid settlements worth $6.6bn combined

Nearly 500,000 died from an opioid overdose between 1999 and 2019

- PMLiVE

Tiziana completes enrolment of first patient cohort in MS expanded access programme

Foralumab has already demonstrated positive results in patients with non-active SPMS

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links